All In Biotech

Drug Trial Radar · NCT00709410

Mass Oral Cholera Vaccination in Zanzibar

Mass Oral Cholera Vaccination in High-risk Populations in Zanzibar: Assessment of Effectiveness and Herd Protection

Last checked: Nov 20, 2026Latest source record: Mar 30, 2012 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

51,151

Actual

Start

Jan 2009

Primary completion

Feb 2009

Study completion Dec 2011

Sponsor

Lead sponsor
International Vaccine InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health and Social Welfare, Zanzibar; National Institute of Cholera and Enteric Diseases, India; Bill and Melinda Gates Foundation; World Health Organization
First posted
Jul 3, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 2 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to conduct cholera vaccinations in high-risk populations in Zanzibar in order to estimate herd protection conferred by the vaccine,estimate effectiveness of the vaccine, and describe the interaction of vaccination and improved water supply on the burden of cholera and diarrhoeal diseases.

Conditions

  • Cholera
  • Diarrhea

Interventions

  • rBS-WC vaccineBiological

    1 mg of recombinant cholera toxin B subunit and approximately 1 x 10\^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Receipt of 2 complete or nearly complete swallowed doses of oral cholera vaccineTime frame: after completion of the vaccination campaign

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ministry of Health and Social Welfare, Zanzibar

    Zanzibar, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.